Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 887 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

NCT01236768
Conditions
Contraception
Interventions
AG200-15, Levora
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more
Conditions
Pharmacokinetics
Interventions
Lurasidone 40 mg, Placebo 40 mg, Ortho Tri-Cyclen
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Conditions
Healthy Volunteers
Interventions
Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay, Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Conditions
Breast Cancer
Interventions
Neratinib, Fulvestrant
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Indianapolis, Indiana • Brewer, Maine • Boston, Massachusetts + 3 more
Conditions
Menopause, Postmenopause
Interventions
Estrogen
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
35 Years to 75 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Houston, Texas
Completed Early Phase 1 Interventional Results available

Transgender Estradiol

NCT04036500
Conditions
Transgender Persons
Interventions
Estradiol
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Systemic Lupus Erythematosus
Interventions
Premarin and Provera
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Conditions
Breast Cancer
Interventions
Cabozantinib, Fulvestrant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers

AFTER: Altering Fat Through Estrogen and Raloxifene

NCT00149604
Conditions
Postmenopause
Interventions
conjugated estrogens, Raloxifene, exercise plus mild caloric restriction for weight loss
Drug · Behavioral
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years to 70 Years · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Not listed Not applicable Interventional Accepts healthy volunteers

Regulation of Cortisol Metabolism and Fat Patterning

NCT00694733
Conditions
Obesity, Menopausal Syndrome
Interventions
Placebo injection, Depo Lupron/Aromatase inhibitor, Depo Lupron/placebo, placebo, Estrogen cream
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 62 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
Interventions
OP-3136, Fulvestrant, Palazestrant
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Ortho-Cyclen, Dolutegravir, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

NCT00544882
Conditions
Healthy
Interventions
DR-1021, Mircette®, Kariva®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Lawrenceville, New Jersey • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

NCT00640224
Conditions
Polycystic Ovary Syndrome
Interventions
rosiglitazone, drospirenone/ethinyl estradiol
Drug
Lead sponsor
Silva Arslanian
Other
Eligibility
10 Years to 20 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Breast Cancer, Infertility
Interventions
Letrozole
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
Interventions
LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more
Conditions
Postmenopausal Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol, Placebo, Progesterone
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
65
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
155
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

NCT03018366
Conditions
Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
Interventions
17beta Estradiol, Transdermal placebo patch, Progesterone, Placebo Pill
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Healthy Volunteers
Interventions
E2086
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Conditions
Pelvic Floor Disorders
Interventions
Postmenopausal, topical vaginal estrogen cream, Placebo Comparator: Postmenopausal, topical placebo cream
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Menopause
Interventions
bioidentical hormone (Biest), bioidentical hormone (Vivelle-Dot)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Prostate Cancer
Interventions
Doxil and Estramustine
Drug
Lead sponsor
Morton Plant Mease Health Care
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Clearwater, Florida